Clinical trials: Head and Neck Cancers- Squamous Cell
Colorectal Cancer, Non-small Cell Lung Cancer
Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib
This is a Phase 1 open-label, dose-escalation trial using "3+3" design, evaluating MM-151 co-administration with MM-121, MM-141, and trametinib at varying dose levels.
- Conditions
- Colorectal Cancer, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck
- Trial name
- NCT02538627
- Testing
- MM-151, MM-121, MM-141
- Where
- 5 sites in United States
- Volunteers
- 5 people
- Sponsor
- Merrimack Pharmaceuticals
Oligometastatic Squamous Cell Carcinoma of the Head and Neck
Pembrolizumab and Radiotherapy for Oligometastatic Head and Neck Cancer
This is a randomized open-label multicentre phase III superiority study of the effect of adding SABR to the standard of care treatment pembrolizumab on progression free survival in patients with oligometastases of a squamous cell…
- Trial name
- PROLoNg (NCT05815927)
- Testing
- Pembrolizumab, stereotattic ablation radiotherapy (SABR)
- Where
- 30 sites in Belgium, Italy and 2 more
- Volunteers
- 200 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Cancer
Thalidomide and Docetaxel in Treating Patients With Advanced Cancer
RATIONALE: Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00049296
- Testing
- docetaxel, thalidomide
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Case Comprehensive Cancer Center
Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Basal Cell Carcinoma of the Lip
Photodynamic Therapy Using HPPH in Treating Patients Undergoing Surgery for Primary or Recurrent Head and Neck Cancer
This phase I trial studies the side effects and best dose of photodynamic therapy using HPPH in treating patients who are undergoing surgery for primary or recurrent head and neck cancer.
- Conditions
- Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Basal Cell Carcinoma of the Lip, Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity
- Trial name
- NCT00470496
- Testing
- HPPH, photodynamic therapy, conventional surgery
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Roswell Park Cancer Institute
Soft Tissue Sarcoma, Colorectal Cancer
A Safety Study of SGN-CD47M in Patients With Solid Tumors
This trial will study SGN-CD47M to find out whether it is an effective treatment for different types of solid tumors and what side effects (unwanted effects) may occur. The study will have two parts.
- Conditions
- Soft Tissue Sarcoma, Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Carcinoma
- Trial name
- NCT03957096
- Testing
- SGN-CD47M
- Where
- 5 sites in United States
- Volunteers
- 16 people
- Sponsor
- Seagen Inc.
Cancer of the Head and Neck
DAHANCA 24: Prognostic Value of 18F-FAZA in Head and Neck Squamous Cell Carcinoma (HNSCC)
Solid tumours contain varying degrees of hypoxia. Studies show hypoxia to be associated with poor local control and survival, as hypoxia is a cause of resistance to radio- and chemotherapy and the development of a more aggressive…
- Trial name
- NCT01017224
- Testing
- 18F-FAZA
- Where
- Denmark
- Volunteers
- 40 people
- Sponsor
- University of Aarhus
Squamous Cell Carcinoma of Head and Neck, Locoregionally Advanced
Phase I Study of BYL719 in Combination With Cisplatin and Radiotherapy in Patients With Squamous Cell Head and Neck Cancer
This is a phase 1 study (the first step in testing a new drug or combination, to see how safe the drug and/or combination are) of investigational agent BYL719 in patients with locally advanced head and neck cancer (LA-SCCHN) in…
- Trial name
- NCT02537223
- Testing
- BYL719, Cisplatin, Intensity modulated radiation therapy (IMRT)
- Where
- Canada
- Volunteers
- 9 people
- Sponsor
- University Health Network, Toronto
Cancer, Carcinoma
PRISM (Panitumumab Regimen In Second-line Monotherapy of Head and Neck Cancer)
To estimate the effect of second-line panitumumab monotherapy on objective response in patients with metastatic or recurrent squamous cell carcinoma of head and neck (SCCHN).
- Conditions
- Cancer, Carcinoma, Head and Neck Cancer, Metastases
- Trial name
- NCT00446446
- Testing
- Panitumumab
- Volunteers
- 52 people
- Sponsor
- Amgen
Cutaneous, Head and Neck Cancer Squamous Cell Carcinoma
Stereotactic Post-operative Radiotherapy for Intraparotid Metastatic Cutaneous Squamous Cell Carcinoma
The purpose of this study is to compare the effectiveness and side effects of stereotactic radiotherapy (5 sessions) against conventional (standard) radiotherapy (20-30 sessions) for the treatment of skin cancer involving the…
- Trial name
- SPRINT (NCT07337161)
- Testing
- SBRT, Standard Radiation
- Where
- Canada
- Volunteers
- 90 people
- Sponsor
- David Palma
Oral Cancer
Therapeutic Efficacy of Quercetin Versus Its Encapsulated Nanoparticle on Tongue Squamous Cell Carcinoma Cell Line
Squamous cell carcinoma (SCC) is the most common oral cavity carcinoma. Conventional therapeutic modalities for oral malignancy include surgery, radiotherapy and chemotherapy alone or in combinations.The major obstacle of using…
- Trial name
- NCT05456022
- Testing
- Quercetin 3,3',4',5,6-Pentahydroxyflavone, 2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4H-1-benzopyran-4-one, Quercetin-encapsulated PLGA-PEG nanoparticles (Nano-QUT), Doxorubicin chemotherapeutic drug as a positive control
- Where
- Egypt
- Volunteers
- 1,000,000 people
- Sponsor
- Cairo University
Squamous Cell Carcinoma of Esophagus
The Effect of Andrographis Paniculata (AP) on Palliative Management of Advanced Esophageal Cancer
This is a prospective cohort study on the effect of Andrographis Paniculata (AP) on palliative management of patients with advanced or metastatic esophageal cancer.
- Trial name
- AP (NCT04196075)
- Testing
- Andrographis Paniculata
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Chinese University of Hong Kong
Recurrent Head and Neck Squamous Cell Carcinoma, Second Primary Squamous Cell Carcinoma of the Head and Neck
Bintrafusp Alfa and Stereotactic Body Radiation Therapy for the Treatment of Recurrent or Second Primary Head and Neck Squamous Cell Cancer
This phase I/II trial studies the side effects and how well bintrafusp alfa and stereotactic body radiation therapy work in treating patients with head and neck squamous cell cancer that has come back (recurrent) or has occurred…
- Trial name
- NCT04220775
- Testing
- Bintrafusp Alfa, Quality-of-Life Assessment, Questionnaire Administration
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- M.D. Anderson Cancer Center
Oral Cancer, Chatbot
Enhancing Oral Cancer Awareness
To evaluate the impact of AI-powered chatbot interactions versus traditional educational handouts on increasing participants' knowledge of oral cancer and its prevention
- Conditions
- Oral Cancer, Chatbot, Patient Education, Prevention
- Trial name
- NCT06682494
- Testing
- Traditional Education, AI-powered Chatbox
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Virginia Commonwealth University
Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)
Trial Evaluating Hypo-fractionated Accelerated Versus Conventional Fractionated Adjuvant RT in Head & Neck Malignancies
Hypo-fractionated radiotherapy reduces the OTT (overall treatment time) which may in turn reduce rapid accelerated repopulation of clonogenic cells during waiting period after surgery.
- Trial name
- Radiotherapy (NCT07573956)
- Testing
- Standard conventionally fractionated PORT, hypo-fractionated PORT
- Where
- India
- Volunteers
- 369 people
- Sponsor
- All India Institute of Medical Sciences
Head and Neck Squamous Cell Carcinoma, Locally Advanced Stage
Molecular-Based Selection of Patients with Head and Neck Squamous Cell Carcinoma: Biomarker Analysis
This is an observational, prospective study enrolling patients who meet the inclusion criteria and provide consent for the use of biopsy samples collected as part of standard clinical practice.
- Trial name
- NCT06905145
- Testing
- Biomarkers evaluation
- Where
- Italy
- Volunteers
- 128 people
- Sponsor
- National Cancer Institute, Naples
Squamous Cell Carcinoma of the Head and Neck
Functional ImaGing of Heterogeneity in Head and Neck Tumors - Validation From Surgical Specimens
The purpose of this study is to investigate if heterogeneity in head and neck squamous cell carcinoma as seen in functional imaging with PET/MR can be correlated to biologic heterogeneity in surgical specimens.
- Trial name
- FIGHHT (NCT03160495)
- Testing
- All patients
- Where
- Denmark
- Volunteers
- 33 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Laryngeal Cancer, Hypopharynx Cancer
SBRT Followed by Chemoimmunotherapy of Toripalimab Plus Docetaxel and Cisplatin for Larynx Preservation in Patients with Locally Regionally Advanced Squamous Cell Carcinoma of the Larynx and Hypopharynx
This trial aims to evaluate the safety and efficiency of SBRT followed by Chemoimmunotherapy of Toripalimab Plus Docetaxel and Cisplatin for Patients with Locally Regionally Advanced Squamous Cell Carcinoma of the Larynx and…
- Trial name
- NCT06611137
- Testing
- SBRT+Toripalimab Plus Docetaxel and Cisplatin
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Sun Yat-sen University
Metastatic Solid Tumor, Recurrent Solid Tumor
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer.
- Conditions
- Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm
- Trial name
- NEXUS-01 (NCT06465069)
- Testing
- LY4052031, Pembrolizumab
- Where
- 39 sites in United States, Australia and 6 more
- Volunteers
- 460 people
- Sponsor
- Eli Lilly and Company
Head and Neck Cancer, Oropharyngeal Cancer
Role of Immune Activation in Response of Head and Neck Squamous Cell Carcinoma to Therapy
The purpose of this study is to investigate the role of the immune system in the response of squamous cell cancers of the head and neck to treatment that includes radiation therapy.
- Conditions
- Head and Neck Cancer, Oropharyngeal Cancer, Human Papillomavirus, Squamous Cell Cancer
- Trial name
- NCT01358097
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Icahn School of Medicine at Mount Sinai
Head and Neck Cancer, Dysphagia
Training Swallowing Initiation During Expiration
Head and neck cancers have escalated to epidemic levels in the United States, and survivors are suffering from life-long, devastating swallowing disorders with limited therapeutic options.
- Conditions
- Head and Neck Cancer, Dysphagia, Oropharyngeal Dysphagia, Oropharynx Squamous Cell Carcinoma
- Trial name
- NCT05278039
- Testing
- Respiratory-Swallow Phase Training, Swallow Practice
- Where
- 2 sites in United States
- Volunteers
- 88 people
- Sponsor
- Northwestern University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.